Xiaohui Du, Belmont, CA (US); John Eksterowicz, Burlingame, CA (US); Valeria R. Fantin, Burlingame, CA (US); Daqing Sun, Foster City, CA (US); Qiuping Ye, Foster City, CA (US); Jared Moore, San Rafael, CA (US); Tatiana Zavorotinskaya, Moraga, CA (US); Brian R. Blank, Daly City, CA (US); Yosup Rew, Foster City, CA (US); Kejia Wu, South San Francisco, CA (US); Liusheng Zhu, Foster City, CA (US); Johnny Pham, San Bruno, CA (US); Hiroyuki Kawai, Pacifica, CA (US); and Chien-Hung Yeh, San Bruno, CA (US)
Assigned to ORIC PHARMACEUTICALS, INC., South San Francisco, CA (US)
Filed by ORIC Pharmaceuticals, Inc., South San Francisco, CA (US)
Filed on May 10, 2024, as Appl. No. 18/660,815.
Application 18/051,125 is a division of application No. 17/083,871, filed on Oct. 29, 2020, granted, now 11,530,236, issued on Dec. 20, 2022.
Application 18/660,815 is a continuation of application No. 18/051,125, filed on Oct. 31, 2022, granted, now 12,018,043.
Claims priority of provisional application 63/088,646, filed on Oct. 7, 2020.
Claims priority of provisional application 62/987,806, filed on Mar. 10, 2020.
Claims priority of provisional application 62/928,138, filed on Oct. 30, 2019.
Prior Publication US 2025/0034198 A1, Jan. 30, 2025
